U.S. pharma giant copyright scrapped two experimental weight loss capsules previous 12 months—a once-daily tablet, lotiglipron, as a result of elevated liver enzymes plus a twice-everyday tablet, danuglipron, as a result of robust Negative effects—but CEO Albert Bourla has mentioned the company is determined to “Enjoy and acquire” while in